BridgeBio Pharma, Inc. — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-02-16

Reporting Person: STEPHENSON BRIAN C (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-16	Common Stock	M	1710	—	Acquired	292635	Direct
2021-02-16	Common Stock	F	592	$64.98	Disposed	292043	Direct
2021-02-17	Common Stock	P	8000	$62.50	Acquired	300043	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-16	Restricted Stock Units	$	M	1710	Disposed		Common Stock (1710)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: Includes 840 shares acquired by the Reporting Person on February 12, 2021 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

F3: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 1,710 shares of Common Stock underlying the Reporting Person's RSUs.

F4: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.